All In Biotech

Drug Trial Radar · NCT07390123

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

A Randomized, Double-blind, and Placebo-controlled Parallel Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 370 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

370

Planned (sponsor's estimate)

Start

Apr 7, 2026

Primary completion

Dec 2027

Study completion Jul 2028

Sponsor

Sponsor type
Industry
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Conditions

  • IgA Nephropathy (IgAN)

Interventions

  • HSK39297Drug

    HSK39297 200mg, once a day; treatment period; 48-weeks fixed dose.

  • PlaceboDrug

    Placebo, once a day; treatment period; 48-weeks fixed dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio to baseline in Urine Protein to Creatinine Ratio (sampled from 24h urine collection) at 36 weeksTime frame: From week 1 to week 36
  2. Annualized total estimated Glomerular Filtration Rate slope over 48 weeksTime frame: From week 1 to week 48

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Huangshan City People's Hospital

    Huangshan City, Anhui, China · Recruiting

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China · Recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Zhanjiang Central Hospital

    Zhanjiang, Guangdong, China · Recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • The Second Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Linyi City People Hospital

    Linyi, Shandong, China · Recruiting

  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Xijing Hospital

    Xi’an, Shanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.